[1]沈建东,戴锋,王晓维,等.异常凝血酶原(PIVKA-Ⅱ)对TACE治疗肝癌疗效预测 [J].介入放射学杂志,2020,29(01):75-78.
 SHEN Jiandong,DAI Feng,WANG Xiaowei,et al.The application of abnormal prothrombin in predicting the efficacy of TACE in the treatment of hepatocellular carcinoma[J].journal interventional radiology,2020,29(01):75-78.
点击复制

异常凝血酶原(PIVKA-Ⅱ)对TACE治疗肝癌疗效预测
()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
29
期数:
2020年01
页码:
75-78
栏目:
临床研究
出版日期:
2020-02-10

文章信息/Info

Title:
The application of abnormal prothrombin in predicting the efficacy of TACE in the treatment of hepatocellular carcinoma
作者:
沈建东戴锋王晓维丁苇薛红戚龙菊付守忠
Author(s):
SHEN Jiandong DAI Feng WANG Xiaowei DING Wei XUE Hong QI Longju FU Shouzhong.
Department of Vascular Intervention, Affiliated Third Hospital of Nantong University, Nantong Municipal Third People’s Hospital, Nantong, Jiangsu Province 226001, China
关键词:
【关键词】 肝细胞肝癌HCC异常凝血酶原PIVKA-Ⅱ预后 
文献标志码:
A
摘要:
【摘要】 目的?探索异常凝血酶原(PIVKA-Ⅱ)在接受TACE的肝癌患者血清中的表达及其临床意义。方法?自2013年1月至2016年1月,接受TACE治疗的肝癌患者170 例纳入本研究,收集TACE术前及术后1个月血清标本。检测血清中PIVKA-Ⅱ和AFP的表达水平,按照实体肿瘤应答评估标准(RECIST)评估抗肿瘤治疗反应­­。根据血清AFP和PIVKA-Ⅱ水平在1个月时与术前基础值相比的变化情况,以介入术后1个月随访腹部增强MRI观察肿瘤大小为标准,分析其与肝癌介入术后治疗反应的关系。结果?患者AFP在介入治疗术前、术后的变化与治疗反应无明显相关性;介入术前、术后PIVKA-Ⅱ的下降情况与治疗反应正相关;PIVKA-Ⅱ和AFP联合观察,与肿瘤的介入治疗反应相关性更明显。且PIVKA-Ⅱ和AFP两种肿瘤指标无明显相关性。结论?PIVKA-Ⅱ水平的降低是肝癌介入栓塞治疗效果和预后判断的良好指标,且与AFP联合判断,效果更确切。

参考文献/References:

1 American Association for the Study of Liver Diseases, European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver DiseasesJ. J Hepatol, 2014, 61: 642-659.
2 Wang Y, Ma L, Yuan ZH, et al. Percutaneous thermal ablation combined with TACE versus TACE monotherapy in the treatment for liver cancer with hepatic vein tumor thrombus: a retrospective studyJ. PLoS One, 2018, 13: e0201525.
3 Yang B, Zheng B, Yang MN, et al. Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinomaJ. Hepatol Int, 2018, 12: 417-428.
4 刘?宓,钟银雪,王?伟,等.血清异常凝血酶原在肝细胞癌诊断中的疗效分析J.中国现代医学杂志, 2017, 27:90-93.
5 罗志坚.肝硬化对原发性肝癌患者行TACE术后临床表现及预后影响D.西宁:青海大学, 2018.
6 Zhang D, Liu Z, Yin X, et al. Prognostic value of PIVKA-Ⅱ in hepatocellular carcinoma patients receiving curative ablation: a systematic review and meta-analysisJ. Int J Biol Markers, 2018, 33: 266-274.
7 张?华,李永兴,毛顺露,等.血清VEGF、p53抗体和AFP对原发性肝细胞癌的诊断价值J.标记免疫分析与临床, 2013, 20:71-74.
8 Shanbhogue A, Karnad A, Prasad S. Tumor response evaluation in oncology: current updateJ. J Comput Assist Tomogr, 2010, 34: 479-484.
9 胡晓菲,於建鹏,王钢胜.PIVKA-Ⅱ和AFP在原发性肝癌中的诊断和疗效监测中的临床应用价值J.临床和实验医学杂志,2017, 16:1473-1476.
10 袁联文,唐 伟,周建平,等.肝癌组织中脱-γ-羧基凝血酶原的测定及意义J.世界华人消化杂志, 2006,14:45-49.
11 马?青,李?慧,刘?航,等.奥沙利铂介入治疗早中期原发性肝癌的疗效分析J.介入放射学杂志, 2019, 28:128-131.
12 宗迎迎,徐?浩,许?伟,等.经肝动脉化疗栓塞联合经皮微波消融序贯治疗早期肝癌的疗效及预后影响因素J.介入放射学杂志,2015, 24:210-214.
13 任?炜,杨?薇.射频消融治疗复发性肝癌疗效及预后因素分析J.介入放射学杂志, 2015, 23:923-927.
14 Hatanaka T, Kakizaki S, Shimada Y, et al. Early decreases in alpha-fetoprotein and des-gamma-carboxy prothrombin predict the antitumor effects of hepatic transarterial infusion chemotherapy with cisplatin (CDDP) powder in patients with advanced hepatocellular carcinomaJ. Intern Med, 2016, 55: 2163-2171.


相似文献/References:

[1]杨柏帅,施裕新,袁 敏,等.TACE治疗既往有肝功能衰竭史肝癌患者七例[J].介入放射学杂志,2014,(09):805.
 YANG Bo shuai,SHI Yu xin,YUAN Min,et al.TACE treatment for patients with inoperable hepatocellular carcinoma and hepatic failure history: initial experience in seven cases[J].journal interventional radiology,2014,(01):805.
[2]邢桃红,牛焕章,周媛媛,等. TACE联合索拉非尼治疗23例中晚期肝细胞肝癌的护理[J].介入放射学杂志,2014,(05):449.
 XING Tao- hong,NIU Huan- zhang,ZHOU Yuan- yuan,et al. Nursing for patients with advanced hepatocellular carcinoma receiving transcatheter arterial chemoembolization combined with sorafenib: initial experience in 23 cases[J].journal interventional radiology,2014,(01):449.
[3]阿布都外力·吾布力卡斯穆,迪里木拉提·巴吾冬,任伟新. 巴塞罗那肝癌B期患者TACE治疗的预后及生存分析[J].介入放射学杂志,2014,(05):435.
 ABUDUWAILI Obulikasimu,DILMURAT Bawudun,REN Wei- xin.. Transcatheter arterial chemoembolization for the treatment of Barcelona stage B hepatocellular carcinoma: analysis of the prognosis and survival[J].journal interventional radiology,2014,(01):435.
[4]王 龙,张 勇,王亚运,等.125I粒子联合经导管动脉化疗栓塞治疗肝细胞肝癌伴门静脉癌栓临床有效性与安全性meta 分析[J].介入放射学杂志,2018,27(05):419.
 WANG Long,ZHANG Yong,WANG Yayun,et al.125I seed implantation combined with TACE for the treatment of HCC complicated by portal vein tumor thrombus: a meta- analysis of its clinical effectiveness and safety[J].journal interventional radiology,2018,27(01):419.
[5]杨柏帅,施裕新,袁 敏,等.终末期肾衰竭肝癌患者TACE术中应用洛铂治疗3例[J].介入放射学杂志,2016,(05):381.
 YANG Bo- shuai,SHI Yu- xin,YUAN Min,et al.Transcatheter arterial chemoembolization using lobaplatin and lipiodol for the treatment of hepatocellular carcinoma associated with end- stage renal failure: report of three cases[J].journal interventional radiology,2016,(01):381.
[6]许 贇,沈 强,王 能,等.微波消融治疗>70岁早期肝细胞肝癌患者效果分析[J].介入放射学杂志,2016,(04):332.
 XU Yun,SHEN Qiang,WANG Neng,et al.Effect analysis of microwave ablation therapy for early hepatocellular carcinoma in patients over 70 years old[J].journal interventional radiology,2016,(01):332.
[7]吴志远,丁晓毅,黄 蔚,等.门脉粒子支架联合载药微球栓塞治疗肝癌7例[J].介入放射学杂志,2017,(02):161.
 WU Zhiyuan,DING Xiaoyi,HUANG Wei,et al.Portal 125I seed stent implantation combined with drug-loaded microsphere embolization for the treatment of HCC: initial results in 7 patients[J].journal interventional radiology,2017,(01):161.
[8]王 燕,王茂强,段 峰.索拉非尼治疗中晚期肝癌预后因素分析[J].介入放射学杂志,2017,(03):258.
 WANG Yan,WANG Maoqiang,DUAN Feng.Prognostic factor analysis of moderate- advanced hepatocellular carcinoma treated with sorafenib [J].journal interventional radiology,2017,(01):258.
[9]余天柱,罗剑钧,颜志平.血管内近程放疗与序贯三维适形放疗治疗门静脉主干癌栓的疗效对比 [J].介入放射学杂志,2017,(09):787.
 YU Tianzhu,LUO Jianjun,YAN Zhiping.Endovascular brachytherapy vs. sequential three- dimensional conformal radiotherapy for the treatment of main portal vein tumor thrombus: a comparative study[J].journal interventional radiology,2017,(01):787.
[10]贾中芝,顾晓诚,蒋国民.门静脉癌栓分型对肝细胞性肝癌治疗方法的选择及患者预后的影响 [J].介入放射学杂志,2017,(10):944.
 JIA Zhongzhi,GU Xiaocheng,JIANG Guomin.The application of portal vein tumor thrombus classification in selecting therapeutic method for HCC patients and in estimating the prognosis[J].journal interventional radiology,2017,(01):944.

备注/Memo

备注/Memo:
(收稿日期:2019-02-06)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2020-02-08